Company: BNBX
Filing Date: 2025-12-30
Form Type: 424B3
Source: 0001104659-25-125037
Chunk: 20

Company: BNB PLUS CORP.
Filing Date: 2025-12-30
Form: 424B3
Chunk 20
---
 ISO 13485 quality system by Alphazyme, LLC (“Alphazyme”), a third-party Contract Development and Manufacturing Organization (“CDMO”) located in the United States, which the Company believes is sufficient for early-stage clinical use of the enzyme. In conjunction with Alphazyme, the Company completed manufacturing process development work on its LineaRNAP to increase the production scale of the enzyme and reduce unit costs. LineaIVT LineaIVT is an innovative integrated system for mRNA manufacturing input materials that combines: (i) the Company’s chemically modified LineaDNA IVT templates; (ii) LineaRNAP; and (iii) a proprietary IVT reaction buffer to simplify mRNA workflows and reduce dsRNA. The LineaIVT platform leverages our patented LineaRNAP’s DNA binding domain to chemically bind to chemically modified LineaDNA IVT templates, enabling the use of a proprietary IVT reaction buffer. Internal data shows that the LineaIVT system can reduce dsRNA contamination between 10x and 50x as compared to conventional system for the manufacture of mRNA while achieving equivalent or greater target mRNA yields. We believe the key advantages of the LineaIVT platform include:

| · | The                                                                                          
 reduction of dsRNA contamination resulting in higher target mRNA yields with the potential   
 to reduce downstream processing steps. dsRNA is a problematic immunogenic byproduct produced 
 during conventional mRNA manufacture;                                                        |

| · | delivery                                                                                   
 of LineaDNA IVT templates in as little as 14 days for milligram scale and 30 days for gram 
 scale;                                                                                     |

| · | reduced                                                                                      
 manufacturing complexities through single sourcing and potentially reduced mRNA purification 
 requirement to meet target quality standards; and                                            |

| · | potentially                                                                      
 enabling mRNA manufacturers to produce mRNA drug substance in less than 45 days. |

<div align='center'>9</div>

Recent Developments

Special Meeting of Stockholders

On December 12, 2025,
the Company held a special meeting of stockholders (the “Special Meeting”). At the Special Meeting, the Company’s stockholders
approved (i) the issuance of shares of Common Stock upon exercise of the Crypto Pre-Funded Warrants and the Series E-2 Warrants,
in accordance with Nasdaq Listing Rules 5635(a) and 5635(d), (ii) an amendment to the Company’s certificate of incorporation
(the “Charter Amendment”) to increase the number of authorized shares of Common Stock from